Li Zhong

Dr. Li Zhong

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
ZSZiyun Shao Sr.
Ziyun Shao Sr.
YFYongwen Feng
Yongwen Feng
LZLi Zhong
Li Zhong
QXQifeng Xie
Qifeng Xie
MLMing Lei
Ming Lei
ZLZhifeng Liu
Zhifeng Liu
Importance: Coronavirus disease 2019 (COVID-19) has become pandemic, causing more than 1.5 million infections and over ten-thousands of deaths in a short period of time worldwide. However, little is known about its pathological mechanism, and reports on clinical study on specific treatment are few. Objective: The purpose of this study is to determine the clinical efficacy of intravenous immunoglobulin (IVIG) therapy in COVID-19 patients. Design, setting and participants: This multicenter retrospective cohort study enrolled 325 adult critical COVID-19 patients, including severe type and critical type, according to the clinical classification defined by National Health Commission of China, in 8 government designated treatment centers in China from Dec 23, 2019 to Mar 31, 2020. Demographic, clinical, treatment, and laboratory data as well as prognosis were extracted from electronic medical records. Exposure: IVIG was exposure factor. Main outcomes and measures: Primary outcomes were the 28-day and 60-day mortality, and secondary outcomes were the total length of in-hospital and the total duration of the disease. Meanwhile, the parameters of inflammation responses and organ functions were measured. The risk factors were determined by COX proportional hazards model. The subgroup analysis was carried out according to clinical classification of COVID-19, IVIG dosage, and timing. Results: In the enrolled 325 patients, 222 (68%) were severe type and 103 (32%) were critical type; 42 (13%) died in 28-day within hospitalization, and 54 (17%) died within 60-day; The death in 60-day includes 6 (3%) severe type patients and 48 (47%) critical type patients. 174 cases were used IVIG, and 151 cases were not. Compared with the baseline characteristics between two groups, the results showed that the patients in IVIG group presented higher Acute Physiology and Chronic Health Evaluation (APACHII) score and Sequential Organ Failure Assessment (SOFA) score, higher plasm levels of IL-6 and lactate, and lower lymphocyte count and oxygenation index (all P <0.05). The 28-day and 60-day mortality were not improved with IVIG in overall cohort. The in-hospital stay and the total duration of disease were longer in IVIG group ( P <0.001). Risk factors were clinical classifications (hazards ratio 0.126, 95% confidence interval 0.039-0.413, P =0.001), and using IVIG (hazards ratio 0.252, 95% confidence interval 0.107-0.591, P =0.002) with COX proportional hazards model. Subgroup analysis showed that only in patients with critical type, IVIG could significantly reduce the 28-day mortality, decrease the inflammatory response, and improve some organ functions (all P 15 g/d) exhibited significant reduction of 60-day mortality in the critical type patients. Conclusions and Relevance: Early administration of IVIG with high dose improves the prognosis of critical type patients with COVID-19. This study provides important information on clinical application of the IVIG in treatment of SARS-CoV-2 infection, including patient selection and administration timing and dosage. Key points: Question: Intravenous immunoglobulin (IVIG) was recommended to treat critical Coronavirus disease 2019 (COVID-19) patients in a few reviews, but the clinical study evidence on its efficacy in COVID-19 patients was lacked. Finding: In this multicenter cohort study that included 325 adult critical patients from 8 treatment centers, the results showed that early administration (admission ≤ 7 days) of IVIG with high dose (> 15 g/d) improves the prognosis of critical type patients with COVID-19. Meaning: This study provides important information on clinical application of IVIG in treatment of SARS-CoV-2 infection, including patient selection, administration timing and dosage.

31 August 2025 in Human Genomics
Verified
Journal Article
Open access
PDF file
LMLifang Mu
Lifang Mu
YZYuxue Zhang
Yuxue Zhang
TYTingting Yuan
Tingting Yuan
DZDingshun Zhang
Dingshun Zhang
ZLZhifeng Liu
Zhifeng Liu
LZLi Zhong
Li Zhong
Sepsis is a major contributor to high morbidity and mortality, often leading to coagulation disorders (CD) in affected individuals. Baicalein, a natural compound with well-established anti-inflammatory properties, shows promise as a potential treatment for sepsis. However, its molecular mechanisms in sepsis-associated CD remain poorly understood. This study investigated the therapeutic effects of baicalein in sepsis and identified candidate genes involved in its mechanism of action. Transcriptomic data, baicalein-related targets from public databases, and CD-related genes from the literature were analyzed to identify potential candidate genes. Machine learning algorithms and expression validation techniques were employed to screen initial candidate genes from the candidates. A nomogram was then constructed based on these candidate genes. Functional enrichment and immune infiltration analyses were conducted to explore the underlying mechanisms, while molecular docking was used to assess interactions between baicalein and the candidate genes. Gene expression was further validated by reverse transcription-quantitative PCR (RT-qPCR). Seven initial candidate genes were identified. Machine learning and expression validation confirmed MMP9, ARG1, and FYN as the final candidate genes involved in sepsis. A highly accurate nomogram, constructed using these candidate genes, demonstrated strong predictive value for sepsis diagnosis. Functional enrichment analysis revealed their pivotal roles in sepsis pathogenesis, while immune infiltration analysis indicated immune dysregulation in sepsis. Additionally, molecular docking revealed strong binding interactions between baicalein and proteins encoded by these candidate genes, supporting further investigation of its therapeutic potential in sepsis. However, these in silico findings are preliminary and require validation through in vitro and in vivo experiments to confirm biological activity. RT-qPCR further validated differential expression of these genes in patients with sepsis compared to healthy controls, confirming the results. This study identified MMP9, ARG1, and FYN as candidate genes in sepsis involved in immune regulation. Additionally, molecular docking revealed strong binding interactions between baicalein and the proteins encoded by these candidate genes, supporting further investigation of its therapeutic potential in sepsis.

6 September 2025 in Heart & Lung
Verified
Journal Article
Closed access
NXNi-Mei Xu
Ni-Mei Xu
LZLi Zhong
Li Zhong
MWMing Wu
Ming Wu
SZShuang Zhang
Shuang Zhang
ZLZhifeng Liu
Zhifeng Liu